Savara (SVRA) AI Stock Analysis

• Market Cap: $1.18B
• Dividend Yield: N/A
• Average Volume (3M): 2.71M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.25
• Revenue Growth: N/A
• EPS Growth: -22.39%
• Country: US
• Employees: 59
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.14
• Shares Outstanding: 203,467,850
• 10 Day Avg. Volume: 1,588,352
• 30 Day Avg. Volume: 2,711,080
• PEG Ratio: -0.14
• Price to Book (P/B): 3.55
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.83
• Enterprise Value/Market Cap: 1.01
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -880.69
• Enterprise Value/Ebitda: -10.19
• 1Y Price Target: $10.17
• Price Target Upside: 74.74% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): -0.41
• Revenue Forecast (FY): $14.01M

• Rating: 47 Neutral
• Price Target: $5.50 ▼(-5.50% Downside)

The score is primarily held down by weak financial performance (no revenue, widening losses, and heavy cash burn with shrinking equity). Technicals are mixed, offering only moderate support, while valuation remains challenging due to negative earnings and no dividend. Corporate events are a partial offset, highlighting potential funding and a clearer path toward a future launch contingent on regulatory outcomes.

Positive Factors

Regulatory Progress & Manufacturing Partnership

Resubmitting the BLA and securing Fujifilm as the drug substance manufacturer plus a Priority Review request materially strengthens the company’s path to approval and commercialization. A stable manufacturing partner reduces supply risk and supports scalable launch planning if approved.

Intellectual Property Protection

European patent activity covering the liquid formulation and a drug‑device combination provides durable exclusivity in key markets. Strong IP around formulation and delivery creates barriers to entry, supports pricing power for a rare‑disease therapy, and enhances commercial defensibility.

Improved Liquidity Position

A materially stronger cash position and proceeds from recent equity financing extend runway for regulatory reviews and commercialization preparations. This reduces near‑term financing pressure, enabling investment in launch readiness, supply chain, and commercial infrastructure if approval occurs.

Negative Factors

No Revenue and Accelerating Cash Burn

The company remains pre‑revenue with widening losses and large operating cash outflows. Persistent negative free cash flow without product sales means ongoing dependence on financing; this structural cash burn elevates dilution and execution risk absent a successful approval and commercial launch.

Eroding Equity and Negative Returns

Sharp decline in shareholder equity and deeply negative returns on equity indicate capital erosion from operating losses. This weakens the balance sheet over time, increasing reliance on external capital and the probability of future dilutive financings that can impair long‑term shareholder value.

Single‑Asset, Binary Clinical Risk

Business and funding are highly contingent on a single investigational therapy. Royalty financing, regulatory timelines, and commercialization progress hinge on approval, creating a binary outcome for company viability. This concentration amplifies regulatory and execution risk over the medium term.

Savara Business Overview & Revenue Model

Company Description

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

How the Company Makes Money

As a clinical-stage biopharmaceutical company, Savara Inc. does not generate revenue from product sales. Instead, the company primarily relies on funding through equity offerings, grants, and strategic partnerships to finance its research and development activities. Significant partnerships with research institutions and pharmaceutical companies may also provide financial support and resources necessary for clinical trials and drug development. Once regulatory approval for its product candidates is obtained, Savara aims to monetize through product sales, licensing agreements, and potential collaborations for commercialization.

Savara Financial Statement Overview

Summary

Financials reflect a development-stage biotech with 0 revenue (2021–TTM), widening net losses (to -$115.6M TTM), and accelerating cash burn (operating/free cash flow about -$99.3M TTM). While leverage is moderate (debt-to-equity ~0.25) and equity remains positive, equity declined sharply to $94.4M TTM, increasing future financing risk.

Income Statement

SVRA shows no meaningful revenue base (revenue is 0 in 2021–2024 and also 0 in TTM (Trailing-Twelve-Months)), which keeps profitability structurally negative. Losses have widened materially: net income declined from -$38.2M (2022) to -$54.7M (2023) to -$95.9M (2024) and -$115.6M in TTM (Trailing-Twelve-Months), indicating rising operating spend without offsetting commercial inflows. A modest positive is that leverage does not appear to be driving the losses (losses look primarily operating), but the earnings trajectory is clearly deteriorating.

Balance Sheet

The balance sheet is supported by a positive equity base ($94.4M in TTM (Trailing-Twelve-Months)) and moderate leverage (debt-to-equity ~0.25 in TTM (Trailing-Twelve-Months)). However, equity has fallen sharply from $171.4M (2024) to $94.4M (TTM), consistent with ongoing losses and cash burn. Returns on equity are deeply negative (about -69% in TTM (Trailing-Twelve-Months)), signaling continued dilution/erosion risk if the company needs additional capital to fund operations.

Cash Flow

Cash generation remains weak with operating cash flow at -$99.3M and free cash flow at -$99.3M in TTM (Trailing-Twelve-Months). Cash burn has accelerated versus prior years (operating cash flow of -$51.1M in 2023 and -$89.1M in 2024), and free cash flow declined again in TTM (Trailing-Twelve-Months) (about -14% growth). A relative positive is that free cash flow broadly tracks net income (free cash flow to net income ~1.0), suggesting losses are largely translating to cash usage rather than being masked by accounting effects.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	257.00K
Gross Profit	-1.36M	-78.03M	-44.26M	-27.88M	-28.99M	-34.78M
EBITDA	-117.49M	-102.27M	-59.13M	-38.01M	-40.50M	-45.85M
Net Income	-115.64M	-95.88M	-54.70M	-38.15M	-43.01M	-49.62M
Balance Sheet
Total Assets	140.92M	212.88M	177.56M	139.78M	176.60M	97.75M
Cash, Cash Equivalents and Short-Term Investments	124.39M	196.33M	162.32M	125.88M	161.17M	82.19M
Total Debt	29.83M	26.73M	26.49M	26.14M	25.79M	25.28M
Total Liabilities	46.54M	41.43M	37.19M	32.00M	32.10M	33.36M
Stockholders Equity	94.39M	171.45M	140.37M	107.78M	144.50M	64.38M
Cash Flow
Free Cash Flow	-99.27M	-89.11M	-51.36M	-34.56M	-40.14M	-43.13M
Operating Cash Flow	-99.26M	-89.09M	-51.06M	-34.55M	-40.08M	-39.84M
Investing Cash Flow	93.02M	-39.94M	-57.12M	52.65M	-69.46M	9.05M
Financing Cash Flow	1.40M	117.58M	82.78M	87.00K	120.81M	3.69M

Savara Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5.82
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SVRA, the sentiment is Neutral. The current price of 5.82 is below the 20-day moving average (MA) of 6.00, above the 50-day MA of 5.62, and above the 200-day MA of 3.66, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 48.16 is Neutral, neither overbought nor oversold. The STOCH value of 69.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SVRA.

Savara Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RIGL	80 Outperform	$680.31M	6.08	220.06%	―	79.13%	2798.12%
OLMA	56 Neutral	$2.13B	-14.98	-59.22%	―	―	17.23%
BCAX	56 Neutral	$917.60M	-7.51	-26.64%	―	―	-103.95%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ANAB	49 Neutral	$1.26B	-16.20	-308.02%	―	196.42%	53.92%
NBTX	48 Neutral	$1.04B	―	―	―	―	―
SVRA	47 Neutral	$1.18B	-10.88	-78.74%	―	―	-22.39%

Savara Corporate Events

Savara Highlights Autoimmune PAP Burden in Updated Presentation

In January 2026, Savara updated its corporate presentation to provide an expanded overview of autoimmune pulmonary alveolar proteinosis (autoimmune PAP), the burden of disease, and the limitations of existing care such as whole lung lavage, an invasive and non‑standardized procedure that does not address the underlying pathophysiology and often must be repeated. The materials underscore significant unmet medical need, including high morbidity, increased healthcare utilization, risk of serious infections, and substantial impact on patients’ daily lives, thereby reinforcing the strategic rationale for Savara’s development of MOLBREEVI and signaling the company’s continued positioning as a specialist player in rare respiratory diseases, with potential implications for future regulatory, clinical, and commercial milestones.

The most recent analyst rating on (SVRA) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Savara stock, see the SVRA Stock Forecast page.

Savara Announces $130 Million Public Offering

On October 29, 2025, Savara Inc. announced the pricing of a $130 million public offering of common stock and pre-funded warrants, with the offering expected to close on October 31, 2025. The proceeds from this offering are intended to support general corporate purposes, including clinical development, regulatory approval pursuits, and commercialization activities for MOLBREEVI in the U.S. and EU, potentially impacting Savara’s operational capabilities and market positioning.

The most recent analyst rating on (SVRA) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Savara stock, see the SVRA Stock Forecast page.

Savara Announces $75M Royalty Funding Agreement

On October 29, 2025, Savara Inc. announced a $75 million royalty funding agreement with RTW Investments, contingent upon FDA approval of MOLBREEVI for autoimmune PAP by March 31, 2027. This agreement is expected to support the U.S. launch of MOLBREEVI, potentially transforming the treatment landscape for this rare disease, and includes provisions for royalty payments based on U.S. net sales, with a buy-back option for Savara under certain conditions.

The most recent analyst rating on (SVRA) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Savara stock, see the SVRA Stock Forecast page.